Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Investing.com - uniQure N.V. (NASDAQ:QURE) reported second quarter revenue that fell short of analyst expectations, though its loss per share was narrower than anticipated. The gene therapy company’s stock tumbled 6.7% premarket following the announcement as investors reacted to the revenue miss and ongoing cash burn despite progress in its clinical pipeline.
The company reported revenue of $5.3 million for the second quarter, slightly below the consensus estimate of $5.4 million and down significantly from $11.1 million in the same period last year. The revenue decline was primarily due to a $7.1 million decrease in collaboration revenue and a $2.1 million reduction in contract manufacturing of HEMGENIX for CSL (OTC:CSLLY) Behring. uniQure posted a loss of $0.69 per share, better than analysts’ expectations of a $0.89 loss.
"We delivered tremendous progress across our business in the first half of 2025, setting the stage for a transformative period ahead for uniQure," said Matt Kapusta, chief executive officer. "With alignment from the FDA on a biological license application pathway and pivotal topline data expected in September, AMT-130 is well-positioned to potentially become the first disease-modifying therapy for people living with Huntington’s disease."
The company ended the quarter with $377 million in cash, cash equivalents and investment securities, up from $367.5 million at the end of 2024. Management expects this will fund operations into the second half of 2027, including the planned U.S. launch of AMT-130 for Huntington’s disease.
uniQure continues to advance its clinical pipeline, with plans to submit a Biologics License Application for AMT-130 in the first quarter of 2026. The company also reported encouraging early data from its first patient treated with AMT-260 for refractory mesial temporal lobe epilepsy, showing a 92% reduction in seizure frequency through the first five months of follow-up.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.